Tessa Therapeutics, a Temasek-backed clinical stage biotech company, is set to enter liquidation after failing to raise more funding for the development of its cancer treatment cell therapies or find a strategic buyer amid a market downturn, The Business Times reported citing the company’s letter to shareholders.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
